2020
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaExternal beam RTVaginal brachytherapyOverall survivalHuman epidermal growth factor receptorModern treatment eraSentinel node samplingRegional nodal recurrenceKaplan-Meier estimatesLog-rank testCox proportional hazardsExternal beam radiotherapyEpidermal growth factor receptorERA treatmentGrowth factor receptorUSC patientsFree survivalNodal recurrenceTreatment eraMultimodality treatmentPatient characteristicsPerioperative periodRegional nodalSerous carcinomaNode sampling
2005
Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer
Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 61: 348-357. PMID: 15667952, DOI: 10.1016/j.ijrobp.2004.06.011.Peer-Reviewed Original ResearchConceptsLocal recurrenceConservative surgeryBreast cancerDistant metastasisInitial diagnosisRadiation therapyEarly-stage invasive breast cancerDistant disease-free survivalEarly-stage breast cancerClinical stage IDisease-free survivalFinal study populationInvasive breast cancerLong-term prognosisProportional hazards modelNonbreast malignanciesActuarial freedomMedian followDistant failureSecond malignanciesIpsilateral breastLocal therapyRegional nodalMedian timeStudy population
1982
Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER)
Kirkwood J, Ariyan S, Nordlund J, Forget B. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER). Cancer 1982, 50: 1299-1303. PMID: 7104973, DOI: 10.1002/1097-0142(19821001)50:7<1299::aid-cncr2820500714>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsBacille Calmette-GuerinMethanol extraction residueCalmette-GuerinThick primary melanomasDefinitive surgical excisionAdjuvant therapyIntralymphatic immunotherapyRegional metastasesRecurrent melanomaRegional nodalClinical presentationSurgical excisionAdjuvant agentLocal instillationIntralymphatic injectionsPrimary tumorPrimary melanomaAntitumor effectsGranulomatous lymphangitisExperimental animalsSubstantial riskComplicationsThick primariesImmunotherapyTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply